Choice of optimal proton pump inhibitor for patients with ischemic heart disease who require dual antiplatelet therapy

O.O. Khaniukov, O.V. Pysarevska, M.G. Getman, T.A. Simonova, T.V. Lakiza

Abstract


High rate of cardiovascular morbidity dictates the need for wide use of antithrombotic agents in clinical practice. Therapy which based on drugs with different mechanisms of action on the thrombocytic component of homeostasis appears to be especially promising as having synergic antiplatelet effect. The most common antiplatelet therapy is a combination of acetylsalicylic acid and clopidogrel usually referred to as a dual antiplatelet therapy (DAT). Current consensus recommends intake of proton pump inhibitors (PPI) during DAT to reduce the risk of gastrointestinal complications. However, recent studies showed that this approach is associated with severe cardiovascular disorders, such as myocardial infarction, stroke, unstable angina, necessity of coronary interventions, and coronary death. So, it seems to be important to develop strategies for the differential use of PPI in patients receiving DAT. The article presents the reviews of the literature on the above issues with the results of studies of various PPI effect on clinical outcomes in patients taking clopidogrel.

Keywords


proton pump inhibitors; dual antiplatelet therapy; drug interaction; pantoprazole; Ulsеpan

References


Каратеев А.Е. Шесть ножей в спину ингибиторам протонной помпы / А.Е. Каратеев // Научно-практическая ревматология. — 2013. — № 51 (3). — С. 332-340.

Колесникова Е.В. Медикаментозная профилактика и лечение гастропатий, связанных с приемом нестероидных противовоспалительных препаратов / Е.В. Колесникова, Т.А. Соломенцева // Сучасна гастроентерологія. — 2016. — № 3 (89). — С. 91-96.

Лапина Т.Л. Фармакологические основы антисекреторной терапии / Т.Л. Лапина // Русский медицинский журнал. — 2005. — № 1. — С. 23-27.

Маев И.В. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме / И.В. Маев, А.А. Самсонов, В.А. Годило-Годлевский // Клиническая медицина. — 2013. — № 5. — С. 15-21.

Марцевич С.Ю. Совместное использование клопидогреля и ингибиторов протонной помпы: есть ли нерешенные вопросы сегодня / С.Ю. Марцевич, А.Ю. Суворов // Рациональная фармакотерапия в кардиологии. — 2014. — № 10. — С. 665-671.

Никонов В.В. Тромбоцитарный гемостаз и антитромбоцитарная терапия при остром коронарном синдроме / В.В. Никонов, Е.И. Киношенко // Медицина неотложных состояний. Избранные клинические лекции. — 2007. — Т. 2. — С. 216-236.

Пархоменко А.Н. Безопасность и эффективность двойной антитромбоцитарной терапии ацетилсалициловой кислотой и клопидогрелем на фоне применения ингибитора протонной помпы после перенесенного острого коронарного синдрома: результаты многоцентрового украинского исследования / А.Н Пархоменко, Я.М. Лутай, О.И. Иркин // Укр. мед. часопис. — 2011. — № 1(81). — С. 45-49.

Харкевич Д.А. Фармакология / Харкевич Д.А. — М.: ГЭОТАР-Медиа, 2006. — 402 с.

Belavic J.M. Ticagrelor: A new option for ACS / J.M. Belavic // Nurse Pract. — 2012. — Vol. 37(3). — P. 9-11.

Bhatt D.L. Clopidogrel with or without omeprazole in coronary heart disease / D.L. Bhatt, B. Cryer, C.F. Contant // N. Engl. J. Med. — 2010. — Vol. 363. — P. 1909-1917.

Bhatt D.L. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events / D.L. Bhatt, K.A. Fox, W. Hacke // N. Engl. J. Med. — 2006. — Vol. 354(16). — P. 1706-1717.

Bhatt D.L. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents / D.L. Bhatt, J. Scheiman, N.S. Abraham // Circulation. — 2008. — Vol. 118. — P. 1894-1909.

Chen Z.M. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled trial / Z.M. Chen, L.X. Jiang, Y.P. Chen // Lancet. — 2005. — Vol. 366(9497). — P. 1607-1621.

Collet J.P. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction / J.P. Collet, J.S. Hulot, A. Pena // Lancet. — 2009. — Vol. 373. — P. 309-317.

Eshaghian S. Role of clopidogrel in managing atherothrombotic cardiovascular disease / S. Eshaghian, S. Kaul, S. Amin // Ann. Intern. Med. — 2007. — Vol. 146(6). — P. 434-441.

Fintel Dan J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options / Dan J. Fintel // Vasc. High Risk Manag. — 2012. — Vol. 8. — P. 77-89.

Inadomi J.M. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs / J.M. Inadomi, L. McIntyre, L. Bernard // Am. J. Gastroente-rol. — 2003. — Vol. 98. — P. 1940-1944.

Gilard M. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole, CLopidogrel, Aspirin) study / M. Gilard, B. Arnaud, J. Cornily // J. Am. Coll. Cardiol. — 2008. — Vol. 51. — P. 256-260.

Hagihara K. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine / K. Hagihara, Y. Nishiya, A. Kurihara // Drug Metab. Pharmacokinet. — 2008. — Vol. 23. — P. 412-420.

Ho P.M. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome / P.M. Ho, T.M. Maddox, L. Wang // J.A.M.A. — 2009. — Vol. 301. — P. 937-944.

Juurlink D.N. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel / D.N. Juurlink, T. Gomes, D.T. Ko // Can. Med. Assoc. J. — 2009. — Vol. 180. — P. 713-718.

Kazui M. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite / M. Kazui, Y. Nishiya, T. Ishizuka // Drug Metab. Dispos. — 2010. — Vol. 38(1). — P. 92-99.

Laine L. Proton pump inhibitor and clopidogrel interaction: fact or fiction? / L.Laine, C. Hennekens // Am. J. Gastroenterol. — 2010. — Vol. 105. — P. 34-41.

Li X.Q. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities / X.Q. Li, T.B. Andersson, M. Ahlstrom // Drug Metab. Disp. — 2004. — Vol. 32. — P. 821-827.

Madanick R.D. Proton pump inhibitor side effect and drug interaction: much ado about nothing? / R.D. Madanick // Cleveland Clin. J. Med. — 2011. — Vol. 78. — P. 39-49.

Mistry S.D. Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence / S.D. Mistry, H.R. Trivedi, D.M. Parmar // Indian. J. Pharmacol. — 2011. — Vol. 43(2). — P. 183-186.

O’Donoghue M.L. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: An analysis of two randomized trials / M.L. O’Donoghue, E. Braunwald, E.M. Antman // Lancet. — 2009. — Vol. 374. — P. 989-997.

Paikin J.S. New antithrombotic agents — insights from clinical trials // J.S. Paikin, J.W. Eikelboom, J.A. Cairns // Nature Rev. Cardiol. — 2010. — Vol. 7(9). — P. 498-509.

Ray W. Outcomes with concurrent use of clopidogrel and proton pump inhibitors: a cohort study / W. Ray, K.T. Murray, M.R. Griffin // Ann. Inern. Med. — 2010. — Vol. 152. — P. 337-345.

Sabatine M.S. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation / M.S. Sabatine, C.P. Cannon, C.M. Gibson // N. Engl. J. Med. — 2005. — Vol. 352(12). — P. 1179-1189.

Simon T. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon, C. Verstuyft, M. Mary-Krause // N. Engl. J. Med. — 2009. — Vol. 360. — P. 363-375.

Stanek E.J. A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clo-pidogrel Medco Outcomes Study / E.J. Stanek, R.E. Aubert, D.A. Flockhart // Program and abstracts of the 32nd Annual SCAI scientific sessions. May 6, 2009, Las Vegas, Nevada. — 2009. — P. 107-115.

Steinhubl S. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interbention: a randomized controlled trial / S. Steinhubl, P. Ber-ger, J. Mann // J.A.M.A. — 2002. — Vol. 288(19). — P. 2411- 2420.

Valgimigli M. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS / M. Valgimigli // European Heart Journal. — 2017. — 0. — P. 1-48. doi: 10.1093/eurheart/ehx419.




DOI: https://doi.org/10.22141/2224-1485.1.57.2018.125495

Copyright (c) 2018 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта